Debolina Ganguly

Title: Debolina Ganguly: Innovator in Cancer Therapy

Introduction

Debolina Ganguly is a prominent inventor based in Memphis, TN (US). She has made significant contributions to the field of cancer research, particularly in developing targeted therapies for therapy-resistant cancers. Her innovative work focuses on enhancing treatment options for patients suffering from glioblastoma.

Latest Patents

Debolina holds a patent for "Bromodomain inhibitors to target therapy-resistant cancer." This patent describes novel inhibitors of the bromodomain of Brahma-related gene 1 (BRG1). The invention outlines methods for treating glioblastoma using these inhibitors in combination with chemotherapeutics, such as DNA alkylating agents. The inhibitors are designed to sensitize glioblastoma cells, including those that are chemoresistant, to DNA alkylating agents like temozolomide and carmustine.

Career Highlights

Debolina is affiliated with the University of Tennessee Research Foundation, where she continues her research and development efforts. Her work has the potential to significantly impact the treatment landscape for glioblastoma, a notoriously aggressive form of brain cancer.

Collaborations

Debolina has collaborated with notable colleagues, including Duane Douglas Miller and Lawrence M Pfeffer. These partnerships enhance her research capabilities and contribute to the advancement of cancer therapies.

Conclusion

Debolina Ganguly's innovative work in developing bromodomain inhibitors represents a significant advancement in the fight against therapy-resistant cancers. Her contributions are paving the way for more effective treatments for glioblastoma patients.